Anti-IAV HA Neutralizing Antibody (V3S-0522-YC864) (CAT#: V3S-0522-YC864)

Send Inquiry
  • fig1
    Figure 1 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in SDS-PAGE
  • fig1
    Figure 2 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in SEC-HPLC
  • fig1
    Figure 3 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA
  • fig1
    Figure 4 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA
  • fig1
    Figure 5 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA
  • fig1
    Figure 6 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA
  • fig1
    Figure 7 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB
  • fig1
    Figure 8 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB
  • fig1
    Figure 9 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB
  • fig1
    Figure 10 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB
  • fig1
    Figure 11 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB
  • fig1
    Figure 12 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB
  • fig1
    Figure 13 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB
  • fig1
    Figure 14 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Influenza A Virus Hemagglutinin. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation.
Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free.
Clonality Monoclonal
Host Species Human
Target Species Influenzavirus A (IAV)
Isotype IgG, κ

Property

Expression Species HEK293F or CHO
Conjugation None
Purity >95%, determined by SDS-PAGE and/or SEC-HPLC
Endotoxin <1 EU/mg, determined by LAL method
Purification Protein A affinity purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C.

Applications

Application WB; DB; ELISA; Neut
Application Notes The antibody is recommended for detection of IAV HA by ELISA, Neut assays.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Flow Cytometry Protocol

Target

Target IAV HA
Alternative Name IAV HA; Influenza A Virus Hemagglutinin; Hemagglutinin HA
Research Area Infectious Disease
Related Disease Infectious disease

Tested Data

SDS-PAGE

Figure 1 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in SDS-PAGE

SDS-PAGE analysis of V3S-0522-YC864 in non-reduced (Lane 1) and reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 135-180 kDa.

Figure 1 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in SDS-PAGE

SEC-HPLC

Figure 2 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in SEC-HPLC

SEC-HPLC analysis of V3S-0522-YC864 shows the purity is>90%.

Figure 2 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in SEC-HPLC

ELISA

Figure 3 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA analysis of V3S-0522-YC864 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC864. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 3 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA

Figure 4 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA analysis of V3S-0522-YC864 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC864. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 4 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA

Figure 5 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA analysis of V3S-0522-YC864 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC864. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 5 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA

Figure 6 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

ELISA analysis of V3S-0522-YC864 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC864. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 6 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in ELISA

WB

Figure 7 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

Western blot analysis of V3S-0522-YC864 was performed by loading Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC864 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 7 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

WB

Figure 8 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

Western blot analysis of V3S-0522-YC864 was performed by loading Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC864 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 8 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

WB

Figure 9 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

Western blot analysis of V3S-0522-YC864 was performed by loading Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC864 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 9 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

WB

Figure 10 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

Western blot analysis of V3S-0522-YC864 was performed by loading Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC864 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 10 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in WB

DB

Figure 11 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

Dot Blot analysis of V3S-0522-YC864 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).

V3S-0522-YC864 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)

Figure 11 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

DB

Figure 12 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

Dot Blot analysis of V3S-0522-YC864 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).

V3S-0522-YC864 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)

Figure 12 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

DB

Figure 13 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

Dot Blot analysis of V3S-0522-YC864 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag).

V3S-0522-YC864 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)

Figure 13 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

DB

Figure 14 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

Dot Blot analysis of V3S-0522-YC864 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His tag).

V3S-0522-YC864 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)

Figure 14 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC864) in DB

For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
ISO 9001 Certified - Creative Biolabs Quality Management System.
Online Inquiry